Key result
rhTPO 300 U/kg/day ranks highest for reducing 28-day mortality and 15000 U/day for shortening ICU stay.
Why the study?
Sepsis remains a common critical illness, prompting an evaluation of the comparative therapeutic value of recombinant human thrombopoietin for sepsis-related thrombocytopenia.
Does recombinant human thrombopoietin (rhTPO) improve platelet levels, reduce transfusion requirements, and decrease mortality in sepsis patients with thrombocytopenia?
Comparison
rhTPO 300 U/kg/day vs rhTPO 15000 U/day vs IVIG vs NAT
Design
Network meta-analysis of randomized controlled trials
Authors
Loading...
May guide rhTPO dosing in critical care; extends indirect comparisons for regimen optimization.
Meta-Analysis (n=963)
Does recombinant human thrombopoietin (rhTPO) improve platelet levels, reduce transfusion requirements, and decrease mortality in sepsis patients with thrombocytopenia?
In patients with sepsis-related thrombocytopenia, rhTPO 300 U/kg/day may be the optimal dose to reduce 28-day mortality and transfusion requirements, while 15000 U/day may best shorten ICU stay and increase early platelet levels.
Chen et al. (2022) conducted a meta-analysis in sepsis-related thrombocytopenia (n=963). recombinant human thrombopoietin (rhTPO) vs. IVIG and NAT was evaluated on platelet levels on the 7th day, requirement of transfusion, 28-day mortality, and length of ICU stay. Recombinant human thrombopoietin 300 U/kg/day ranked highest for reducing 28-day mortality (SUCRA 85.5%), while 15000 U/day ranked highest for shortening ICU stay (SUCRA 95.9%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: